January 2018 in “Springer eBooks” Terbinafine is the most effective medicine for fungal nail infections, especially for diabetics and those with weak immune systems.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
3 citations
,
April 2025 in “International Journal of Pharmaceutics” Nanocrystals improve alopecia areata treatment by better targeting hair follicles.
February 2026 in “Clinical Drug Investigation” Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.
40 citations
,
November 2017 in “International journal of nanomedicine” DA liposomes with chloramphenicol effectively target hair follicles and combat MRSA with minimal skin toxicity.
June 2025 in “Natural Product Communications” Researchers created 10 new compounds similar to cercidin, which could lead to new antibiotics.
8 citations
,
January 2023 in “Journal of Research in Pharmacy” Compounds from turmeric and bitter show strong potential as antiviral agents against the influenza A virus.
August 2023 in “Journal of inflammation research” An elderly Chinese man lost all his hair after taking a new heart medication.
29 citations
,
November 2021 in “FEBS Open Bio” Cepharanthine analogues, especially tetrandrine, show potential for treating COVID-19.
6 citations
,
March 2023 in “Frontiers in Cellular and Infection Microbiology” Golvatinib shows promise as a treatment for Omicron in elderly patients.
2 citations
,
January 2025 in “Journal of Clinical Immunology” Clitocybin A can promote hair growth by increasing cell proliferation.
5 citations
,
May 2020 in “Clinical and Experimental Dermatology” Clascoterone may be a promising treatment for hair loss.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” 1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
20 citations
,
February 2017 in “European journal of pharmaceutical sciences” The MPA-ISO cocrystal improved solubility and dissolution rate, while the others did not.
8 citations
,
July 2023 in “Frontiers in Pharmacology” Cepharanthine shows promise as a COVID-19 treatment.
February 2010 in “Journal of the American Academy of Dermatology” Lactic acid cream can help improve skin bumps known as eruptive vellus hair cysts.
2 citations
,
April 2019 in “Journal of the American Society of Nephrology” Fluconazole might be a new treatment for a type of diabetes that affects water balance in the body.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
4 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Abrocitinib may help treat alopecia areata effectively with mild side effects.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
Cepharanthine could be a strong antiviral against COVID-19.
January 2026 in “Journal of Ethnopharmacology” Cedrol promotes hair growth better than baricitinib by regulating immune cells.
3 citations
,
January 2021 in “Therapeutic advances in infectious disease” A 9-year-old girl with a healthy immune system was successfully treated for a severe fungal scalp infection caused by Microsporum audouinii.
January 2026 in “Physical Education Health and Social Sciences” Combining probiotics, clotrimazole gel, and laser therapy improves treatment for recurrent yeast infections.
1 citations
,
August 2023 in “The journal of pharmacology and experimental therapeutics/The Journal of pharmacology and experimental therapeutics” Kir6.1 mutations in Cantú syndrome increase channel sensitivity and hyperpolarization, while SUR2B mutations do not.